RIGL Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Company profile
Ticker
RIGL
Exchange
Website
CEO
Raul Rodriguez
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943248524
RIGL stock data
()
News
Rigel Pharmaceuticals Granted U.S. Patent Titled 'RIP1 inhibitory compounds and methods for making and using the same'
13 Apr 21
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
13 Apr 21
Rigel Pharmaceuticals Phase 2 Clinical Trial Of Fostamatinib In Hospitalized Patients with COVID-19 Met Primary Endpoint
13 Apr 21
Rigel Announces Closing Of Strategic Collaboration With Lilly; Says Agreement Is Effective As Of Mar. 27, Rigel Has Received $125M Upfront Payment
7 Apr 21
Rigel Announces Completion Of Patient Enrollment For NIH/NHLBI-Sponsored Phase 2 Trial Of Fostamatinib In Hospitalized COVID-19 Patients
11 Mar 21
Press releases
Thinking about buying stock in Rigel Pharmaceuticals, Checkpoint Therapeutics, GT Biopharma, ICICI Bank, or Arbutus Biopharma?
13 Apr 21
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
13 Apr 21
Rigel Announces Closing of Strategic Collaboration with Lilly
7 Apr 21
Thinking about buying stock in Rigel Pharmaceuticals, AMC Entertainment, Vir Biotechnology, Oncolytics Biotech, or Senseonics Holdings?
12 Mar 21
Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients
11 Mar 21
Calendar
2 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 30.37M | 30.37M | 30.37M | 30.37M | 30.37M | 30.37M |
| Cash burn (monthly) | 2.06M | (positive/no burn) | 6.28M | 2.41M | 5.19M | 4.35M |
| Cash used (since last report) | 7.11M | n/a | 21.6M | 8.31M | 17.87M | 14.97M |
| Cash remaining | 23.27M | n/a | 8.77M | 22.06M | 12.51M | 15.41M |
| Runway (months of cash) | 11.3 | n/a | 1.4 | 9.1 | 2.4 | 3.5 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Apr 21 | Raul R Rodriguez | Stock Option Common Stock | Grant | Aquire A | No | No | 2.42 | 162,500 | 393.25K | 162,500 |
| 1 Apr 21 | Dean L Schorno | Stock Option Common Stock | Grant | Aquire A | No | No | 2.42 | 50,000 | 121K | 50,000 |
| 1 Apr 21 | Dolly Vance | Stock Option Common Stock | Grant | Aquire A | No | No | 2.42 | 37,500 | 90.75K | 37,500 |
| 27 Jan 21 | Raul R Rodriguez | Stock Option(right to buy) Common Stock | Grant | Aquire A | No | No | 3.54 | 525,000 | 1.86M | 525,000 |
| 27 Jan 21 | Dolly Vance | Stock Option(right to buy) Common Stock | Grant | Aquire A | No | No | 3.54 | 125,000 | 442.5K | 125,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
82.6% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 150 |
| Opened positions | 24 |
| Closed positions | 15 |
| Increased positions | 42 |
| Reduced positions | 52 |
13F shares |
Current |
|---|---|
| Total value | 1.07B |
| Total shares | 140.57M |
| Total puts | 483.1K |
| Total calls | 613.7K |
| Total put/call ratio | 0.8 |
Largest owners |
Shares | Value |
|---|---|---|
| FMR | 20.91M | $73.2M |
| BLK Blackrock | 17.49M | $61.23M |
| Wellington Management | 11.2M | $39.2M |
| STT State Street | 9.36M | $32.77M |
| Vanguard | 9.15M | $32.01M |
| Tamarack Advisers | 7.45M | $25.96M |
| Citadel Advisors | 6.34M | $22.19M |
| MS Morgan Stanley | 5.23M | $18.29M |
| IVZ Invesco | 5.13M | $17.94M |
| Rock Springs Capital Management | 4.74M | $16.6M |
Financial report summary
?Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
absenteeism, abundance, accessed, accessibility, accuracy, activist, adapt, adaptive, adequacy, advocacy, advocating, afflicted, AgreementSM, Alabama, ALI, alleviating, anesthesiologist, Antitrust, arm, ascertain, ASCO, barrier, Biden, biomarker, Biovitrum, Birmingham, border, brain, Brazil, breakdown, Britain, British, burdensome, cap, career, CCPA, cessation, Chemical, cITP, CJEU, closure, CLR, CMT, CNS, College, commerce, Commissioner, Condensed, confidence, conflicting, Consortium, constitutionality, contemplated, conventional, costliest, COVID, CPRA, CTR, cybersecurity, David, deceptive, deny, depletion, deploy, deployed, deprive, Digital, distancing, diverge, divergent, DOD, donor, draft, dysfunction, Ebola, edema, EEA, Eli, embedded, endeavor, endothelial, England, enveloped, epithelial, ESG, evolution, expedited, extracellular, fast, faster, fined, Foundation, France, fundamentally, gamma, GBM, GDPR, Genentech, Germany, glioblastoma, Great, Haematology, harbor, Harvard, Heart, highlighting, home, HSR, hyperinflammation, hyperinflammatory, Ichiro, IgG, ill, impede, Imperial, inclusion, India, infection, inflation, Inline, Inova, interference, Interferon, Internationally, ion, Ireland, Italy, Jazz, join, jointly, Justice, KeytrudaTM, landscape, League, leave, lectin, led, Lilly, live, macrophage, macrovascular, magnitude, matched, mediated, MHRA, micro, misrepresentative, misuse, MIT, mortality, movement, myocardial, Nakano, narrowed, nation, national, nationwide, necessitate, Neurosurgery, neutrophil, NHS, NIH, NOL, Nuclear, nurse, opportunistic, opportunistically, opposition, parallel, partnership, pathology, pause, paused, penetrating, perspective, PFS, pneumonia, poor, poster, preferential, presidential, Professor, prognostic, prolonged, pulmonary, pursuit, qualification, Radiological, Rain, randomly, recession, recurrent, redacted, reexamining, refill, regularly, remote, remotely, repayable, repurposing, resection, residence, residency, residing, respiratory, retention, revised, Rheumatism, RIP, risky, rulemaking, ruxolitinib, SAE, salesforce, Scotland, Scottish, sequester, serum, Shareholder, shelter, Shield, ship, shipping, shock, shop, simply, slowdown, SOC, software, Southampton, Spain, speaker, speculative, store, substance, supervisory, Supreme, surface, surge, surgical, Swedish, Switzerland, theft, thought, thromboinflammation, tie, timeframe, timescale, tract, traditional, translational, UKRI, undertaken, unemployment, unenforceable, unvaried, vendor, viability, virtual, virtually, vivo, wAIHA, whichever, widespread, worsening, Zealand, Zika
Removed:
accelerated, accident, calendar, Cantor, delisted, delisting, Duliege, electrical, feedback, grace, IgA, regain, unvested
Financial reports
10-K
2020 FY
Annual report
2 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
4 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
Current reports
8-K
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
2 Mar 21
8-K
Entry into a Material Definitive Agreement
18 Feb 21
8-K
Departure of Directors or Certain Officers
3 Feb 21
8-K
Rigel Pharmaceuticals Provides Business Update
11 Jan 21
8-K
Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update
5 Nov 20
8-K
Departure of Directors or Certain Officers
8 Oct 20
8-K
Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program
4 Aug 20
8-K
Departure of Directors or Certain Officers
15 May 20
8-K
Rigel Reports First Quarter 2020 Financial Results and Provides Business Update
5 May 20
8-K
Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
27 Feb 20
Registration and prospectus
S-8
Registration of securities for employees
4 Aug 20
424B5
Prospectus supplement for primary offering
4 Aug 20
S-8
Registration of securities for employees
6 Aug 19
S-8
Registration of securities for employees
8 Aug 18
424B5
Prospectus supplement for primary offering
19 Apr 18
424B5
Prospectus supplement for primary offering
17 Apr 18
S-3
Shelf registration
8 Mar 18
S-8
Registration of securities for employees
6 Nov 17
424B5
Prospectus supplement for primary offering
4 Oct 17
424B5
Prospectus supplement for primary offering
2 Oct 17
Proxies
DEF 14A
Definitive proxy
6 Apr 21
DEFA14A
Additional proxy soliciting materials
1 May 20
DEFA14A
Additional proxy soliciting materials
1 Apr 20
DEF 14A
Definitive proxy
1 Apr 20
DEFA14A
Additional proxy soliciting materials
9 Apr 19
DEF 14A
Definitive proxy
9 Apr 19
DEF 14A
Definitive proxy
3 Apr 18
DEFA14A
Additional proxy soliciting materials
3 Apr 18
PRE 14A
Preliminary proxy
22 Mar 18
DEF 14A
Definitive proxy
28 Mar 17
Other
CT ORDER
Confidential treatment order
24 Apr 20
CT ORDER
Confidential treatment order
24 Apr 20
CT ORDER
Confidential treatment order
16 Jan 20
CT ORDER
Confidential treatment order
15 Jan 20
CT ORDER
Confidential treatment order
15 Jan 20
CT ORDER
Confidential treatment order
20 Mar 19
CORRESP
Correspondence with SEC
1 Apr 18
EFFECT
Notice of effectiveness
1 Apr 18
CT ORDER
Confidential treatment order
14 Mar 18
CT ORDER
Confidential treatment order
17 Nov 16
Ownership
4
RIGEL PHARMACEUTICALS / DOLLY VANCE ownership change
2 Apr 21
4
RIGEL PHARMACEUTICALS / Dean L Schorno ownership change
2 Apr 21
4
RIGEL PHARMACEUTICALS / RAUL R RODRIGUEZ ownership change
2 Apr 21
SC 13G/A
RIGEL PHARMACEUTICALS / INTEGRATED CORE STRATEGIES ownership change
15 Feb 21
SC 13G
RIGEL PHARMACEUTICALS / STATE STREET ownership change
11 Feb 21
SC 13G/A
RIGEL PHARMACEUTICALS / VANGUARD ownership change
9 Feb 21
SC 13G/A
RIGEL PHARMACEUTICALS / FMR ownership change
8 Feb 21
SC 13G/A
RIGEL PHARMACEUTICALS / WELLINGTON MANAGEMENT ownership change
4 Feb 21
4
RIGEL PHARMACEUTICALS / Wolfgang Dummer ownership change
29 Jan 21
4
RIGEL PHARMACEUTICALS / David A Santos ownership change
29 Jan 21
Patents
APP
Utility
Nrf2 Activating Compounds and Uses Thereof
18 Mar 21
Aspects of the present disclosure include compounds that activate Nrf2.
APP
Utility
Tyrosine Kinase Inhibitors
18 Mar 21
Inventors: Ihab Darwish, Jiaxin Yu, Rao Kolluri, Sacha Holland
GRANT
Utility
Amide compounds and method for making and using
16 Mar 21
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors.
APP
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
11 Mar 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
APP
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
11 Mar 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP 1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Transcripts
2020 Q4
Earnings call transcript
3 Mar 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
4 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q4
Earnings call transcript
27 Feb 20
2019 Q3
Earnings call transcript
8 Nov 19
2019 Q2
Earnings call transcript
6 Aug 19
2019 Q1
Earnings call transcript
7 May 19
2018 Q4
Earnings call transcript
1 Mar 19
2018 Q3
Earnings call transcript
6 Nov 18
Reddit threads
Morning Update for Tuesday, 04/13/21
13 Apr 21
Watchlist for 4/13/2021
13 Apr 21
r/Stocks Daily Discussion & Technicals Tuesday - Apr 13, 2021
13 Apr 21
Daily Plays - April 13, 2021
13 Apr 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - April 13, 2021
12 Apr 21
Let me know what stocks you want to go green and I'll sell my shares! Works every time.
9 Apr 21
Anyone want to compare luggage? I’ll go first. My bags are as follows- 50k shares of $CBDL that’s down 85%, 5k shares of $OZSC that’s down 65%, and 25k shares of $CBDD that’s down 53%.
8 Apr 21
Anyone notice how most of the top DD posted on here this year, came around the peak of the stock and the stock has only fallen since?
8 Apr 21
Daily Discussion Thread - April 6th, 2021
6 Apr 21
88 Energy Ltd. $EEENF Quick timeline, some expectations & DD summary!
26 Mar 21